Research programme: GPCR-targeting biotherapeutics - MorphoSys/G7 Therapeutics

Drug Profile

Research programme: GPCR-targeting biotherapeutics - MorphoSys/G7 Therapeutics

Latest Information Update: 02 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator G7 Therapeutics; MorphoSys
  • Developer MorphoSys
  • Class Antibodies
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 30 Nov 2016 Heptares signs a share purchase agreement for the 100% acquisition in G7 Therapeutics
  • 29 Nov 2016 Heptares Therapeutics plans to acquire G7 Therapeutics
  • 04 Aug 2015 MorphoSys and G7 Therapeutics agree to co-develop GPCR-targeting antibodies in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top